282 related articles for article (PubMed ID: 26506944)
1. Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH.
Wang Y; Liu Z; Zou W; Hong H; Fang H; Tong W
Biomark Med; 2015; 9(11):1189-200. PubMed ID: 26506944
[TBL] [Abstract][Full Text] [Related]
2. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.
Leti F; Malenica I; Doshi M; Courtright A; Van Keuren-Jensen K; Legendre C; Still CD; Gerhard GS; DiStefano JK
Transl Res; 2015 Sep; 166(3):304-14. PubMed ID: 26001595
[TBL] [Abstract][Full Text] [Related]
3. 'Micro-managers' of hepatic lipid metabolism and NAFLD.
Liu W; Cao H; Yan J; Huang R; Ying H
Wiley Interdiscip Rev RNA; 2015; 6(5):581-93. PubMed ID: 26198708
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway.
Hur W; Lee JH; Kim SW; Kim JH; Bae SH; Kim M; Hwang D; Kim YS; Park T; Um SJ; Song BJ; Yoon SK
Int J Biochem Cell Biol; 2015 Jul; 64():265-76. PubMed ID: 25957914
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.
Liu XL; Cao HX; Fan JG
J Dig Dis; 2016 Nov; 17(11):708-715. PubMed ID: 27628945
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury.
Markovic J; Sharma AD; Balakrishnan A
Cells; 2020 Jul; 9(8):. PubMed ID: 32717951
[TBL] [Abstract][Full Text] [Related]
8. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.
Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Kato J; Tokunaga S; Sugihara TA; Hara Y; Hino K; Murawaki Y
PLoS One; 2016; 11(5):e0154676. PubMed ID: 27135827
[TBL] [Abstract][Full Text] [Related]
9. MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a.
Du J; Niu X; Wang Y; Kong L; Wang R; Zhang Y; Zhao S; Nan Y
Sci Rep; 2015 Nov; 5():16163. PubMed ID: 26537990
[TBL] [Abstract][Full Text] [Related]
10. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
[TBL] [Abstract][Full Text] [Related]
11. Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL/NASH: Impact of LPS/TLR-4/FoxO3 pathway.
Samy AM; Kandeil MA; Sabry D; Abdel-Ghany AA; Mahmoud MO
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300631. PubMed ID: 38574101
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.
Katsura A; Morishita A; Iwama H; Tani J; Sakamoto T; Tatsuta M; Toyota Y; Fujita K; Kato K; Maeda E; Nomura T; Miyoshi H; Yoneyama H; Himoto T; Fujiwara S; Kobara H; Mori H; Niki T; Ono M; Hirashima M; Masaki T
Int J Mol Med; 2015 Apr; 35(4):877-84. PubMed ID: 25672270
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z; Dou G; Wang L
Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs in fatty liver disease.
Sobolewski C; Calo N; Portius D; Foti M
Semin Liver Dis; 2015 Feb; 35(1):12-25. PubMed ID: 25632931
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.
Cariello M; Piccinin E; Moschetta A
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1519-1539. PubMed ID: 33545430
[TBL] [Abstract][Full Text] [Related]
16. Circulating miRNAs associated with nonalcoholic fatty liver disease.
Atic AI; Thiele M; Munk A; Dalgaard LT
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C588-C602. PubMed ID: 36645666
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
[TBL] [Abstract][Full Text] [Related]
18. miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
Auguet T; Aragonès G; Berlanga A; Guiu-Jurado E; Martí A; Martínez S; Sabench F; Hernández M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669236
[TBL] [Abstract][Full Text] [Related]
19. miRNAs in non-alcoholic fatty liver disease.
He Z; Hu C; Jia W
Front Med; 2016 Dec; 10(4):389-396. PubMed ID: 27680976
[TBL] [Abstract][Full Text] [Related]
20. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
Rodrigues PM; Afonso MB; Simão AL; Carvalho CC; Trindade A; Duarte A; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM; Castro RE
Cell Death Dis; 2017 Apr; 8(4):e2748. PubMed ID: 28406477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
